Skip to main content

Table 2 Survival characteristics of patients

From: The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas

  mOS
in months
  mOS
in months
p
Age < 65 17.5 > 65 12 < 0.001
KPS > 70 19 < 70 12 < 0.001
Sex M 15 F 13 n.s.
EOR GTR 15 STR 13 n.s.
Histo AA 41 GBM 13 < 0.0001
MGMT MGMT+ 20 MGMT- 12 < 0.001
MGMT AA MGMT+ 41,5 MGMT- 18 n.d.
MGMT GBM MGMT+ 15 MGMT- 12 n.s.
IDH IDH+ 51 IDH- 13 < 0.0001
IDH AA IDH+ 54 IDH- 16 < 0.0001
IDH GBM IDH+ 11 IDH- 13 n.s.
EGFR EGFR+ 14 EGFR- 14 n.s.
EGFR AA EGFR+ 9 EGFR- 42 < 0.05
EGFR GBM EGFR+ 14 EGFR- 12 n.s.
IDH/MGMT IDH+/MGMT+ 46,5 IDH+/MGMT- 64 n.d.
IDH/MGMT IDH+/MGMT+ 46,5 IDH−/MGMT+ 15 < 0,00001
IDH/MGMT IDH+/MGMT+ 46,5 IDH−/MGMT- 12 n.s.
IDH/MGMT IDH−/MGMT+ 15 IDH+/MGMT- 64 n.d.
IDH/MGMT IDH−/MGMT+ 15 IDH−/MGMT- 12 n.s.
IDH/MGMT IDH+/MGMT- 64 IDH−/MGMT- 12 n.d.
  1. mOS median overall survival in months, p p-value by Logrank test with a value less than 0.05 indicating statistical significance, Histo histological diagnosis, AA anaplastic astrocytoma, GBM glioblastoma, GTR gross total resection, STR subtotal resection, M male, F female, n.s. not significant, n.d. not determined, KPS Karnofsky Performance Scale, EOR extent of resection, IDH+ IDH1 or IDH2 mutation, IDH- no IDH1 or IDH2 mutation, MGMT+ promoter methylation, MGMT- no promoter methylation, EGFR+ amplification, EGFR- no amplification